DK3266446T3 - Øjenpræparat omfattende ricinusolie og triglycerid med mediumkæde - Google Patents
Øjenpræparat omfattende ricinusolie og triglycerid med mediumkæde Download PDFInfo
- Publication number
- DK3266446T3 DK3266446T3 DK16382321.4T DK16382321T DK3266446T3 DK 3266446 T3 DK3266446 T3 DK 3266446T3 DK 16382321 T DK16382321 T DK 16382321T DK 3266446 T3 DK3266446 T3 DK 3266446T3
- Authority
- DK
- Denmark
- Prior art keywords
- castor oil
- composition
- keratitis
- medium chain
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Nanotechnology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Claims (15)
1. Sterilt øjenpræparat omfattende: a) en oliefase omfattende ricinusolie og et triglycerid med mediumkæde, b) ét eller flere overfladeaktive midler og c) en vandig fase; hvor præparatet har en pH fra 5,0 til 9,0.
2. Præparat ifølge krav 1, hvor ricinusolien og triglyceridet med mediumkæde er i et vægtforhold på fra 50:1 til 1:50, fortrinsvis fra 10:1 til 1:10, mere foretrukket fra 1,5:1 til 1:1,5, mere foretrukket 1:1.
3. Præparat ifølge et hvilket som helst af de foregående krav, hvor den samlede mængde ricinusolie og triglycerid med mediumkæde er fra 0,05 til 70 vægtprocent i forhold til præparatets samlede vægt.
4. Præparat ifølge et hvilket som helst af de foregående krav, hvor triglyceridet med mediumkæde er capryl/caprinsyre-triglycerid.
5. Præparat ifølge et hvilket som helst af de foregående krav, der yderligere omfatter én eller flere andre olier end ricinusolien og triglyceridet med mediumkæde, fortrinsvis hvor den ene eller de flere andre olier end ricinusolien og triglyceridet med mediumkæde er valgt fra gruppen bestående af ethyloleat, isopropylmyristat, isopropylpalmitat, isopropylisostearat, isostearylisostearat, myristyllactat, ethylhexylhydroxystearat, ethyl-hexylpelargonat, triethylhexanoin, isohexadecan, mineralolie, vegetabilsk olie, især arganolie, triisononanoin, C12-15 alkylbenzoat og blandinger deraf.
6. Præparat ifølge et hvilket som helst af de foregående krav, hvor den resulterende hydrofile-lipofile balanceværdi af det ene eller de flere overfladeaktive midler er fra 10 til 16, fortrinsvis hvor det ene eller de flere overfladeaktive midler er valgt fra gruppen bestående af polyoxyl 35-ricinusolie, polyoxyethylen 20-sorbitanmonooleat, sorbitan-laurat og blandinger deraf, mere foretrukket hvor det overfladeaktive middel er polyoxyl 35-ricinusolie.
7. Præparat ifølge et hvilket som helst af de foregående krav, hvor den samlede mængde overfladeaktivt middel er fra 0,1 til 40 vægtprocent i forhold til præparatets samlede vægt.
8. Præparat ifølge et hvilket som helst af de foregående krav, der yderligere omfatter ét eller flere tonicitetsjusterende midler, fortrinsvis hvor det ene eller de flere tonicitetsju-sterende midler er valgt fra gruppen bestående af natriumchlorid, glycerin, propylengly-col og blandinger deraf.
9. Præparat ifølge et hvilket som helst af de foregående krav, der yderligere omfatter ét eller flere pH-justeringsmidler, fortrinsvis hvor det ene eller de flere pH-justeringsmidler er valgt fra gruppen bestående af tris(hydroxymethyl)aminomethan, tris(hydroxy-methyl)aminomethanhydrochlorid, kaliumdihydrogenphosphat, dinatriumhydrogen-phosphat og blandinger deraf.
10. Præparat ifølge et hvilket som helst af de foregående krav, der yderligere omfatter fra 0,1 til 10 vægtprocent af ét eller flere viskositetsforøgende midler, som er valgt fra gruppen bestående af natriumalginat, polyvinylpyrrolidon, gellangummi, chitosan eller et derivat deraf og blandinger deraf, i forhold til præparatets samlede vægt.
11. Præparat ifølge et hvilket som helst af de foregående krav, der yderligere omfatter én eller flere aktive ingredienser valgt fra gruppen bestående af tranebærekstrakt, maquibærekstrakt, retinylacetat, retinylpalmitat, retinylpropionat, cholecalciferol, ergo-calciferol, tocopherylacetat og blandinger deraf.
12. Præparat ifølge et hvilket som helst af de foregående krav, hvor præparatet omfatter mindst 80 vægtprocent vand i forhold til præparatets samlede vægt.
13. Præparat ifølge et hvilket som helst af de foregående krav i form af en nanoemulsi-on.
14. Præparat som defineret i et hvilket som helst af de foregående krav til anvendelse i medicin.
15. Præparat som defineret i et hvilket som helst af kravene 1 til 13 til anvendelse til behandling og/eller forebyggelse af en øjensygdom valgt fra gruppen bestående af tørre øjne (herunder keratokonjunktivitis sicca, xeroftalmi, xerose og Sjogrens syndrom), konjunktivitis (herunder allergisk konjunktivitis, vernal keratokonjunktivitis, atopisk keratokonjunktivitis, pemfigoid, Stevens-Johnsons syndrom, toksisk epidermal nekrolyse, viral keratokonjunktivitis og limbisk keratokonjunktivitis), dermatitis (herunder kontaktdermatitis, atopisk dermatitis), blefaritis (herunder kronisk forreste blefaritis, kronisk bageste blefaritis), entropion (herunder paralytisk entropion, involutionelt entropion), floppy eyelid-syndrom, oftalmopati i skjoldbruskkirtlen, pterygium, konjunktivo-chalase, epitelskade induceret af konserveringsmidler, epitel- eller forkammerskader induceret af øjenkirurgi, limbalcellemangel, hornhindesår induceret af fysiske eller kemiske midler, keratitis (herunder stromal nekrotisk keratitis, Cogans syndrom, ulcus Mooren, neurotrofisk keratitis, eksponeringskeratitis, krystallinsk infektiøs keratitis, Thygesons overfladiske punkterede keratitis, filamentøs keratitis, tilbagevendende hornhindeepitel-erosioner, epiteldystrofier og Meesmanns dystrofi) og episkleritis.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16382321.4A EP3266446B1 (en) | 2016-07-07 | 2016-07-07 | Ophthalmic composition comprising castor oil and medium chain triglyceride |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3266446T3 true DK3266446T3 (da) | 2019-02-11 |
Family
ID=56404062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16382321.4T DK3266446T3 (da) | 2016-07-07 | 2016-07-07 | Øjenpræparat omfattende ricinusolie og triglycerid med mediumkæde |
Country Status (14)
Country | Link |
---|---|
US (1) | US10660848B2 (da) |
EP (1) | EP3266446B1 (da) |
JP (1) | JP7224095B2 (da) |
CN (1) | CN107582605A (da) |
DK (1) | DK3266446T3 (da) |
ES (1) | ES2706535T3 (da) |
HR (1) | HRP20190036T1 (da) |
JO (1) | JOP20170147B1 (da) |
LT (1) | LT3266446T (da) |
PL (1) | PL3266446T3 (da) |
PT (1) | PT3266446T (da) |
RS (1) | RS58292B1 (da) |
RU (1) | RU2756758C2 (da) |
SI (1) | SI3266446T1 (da) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109689161A (zh) | 2016-08-19 | 2019-04-26 | 阿克里维斯塔有限责任公司 | 诊断和治疗干眼综合症的方法以及用于治疗人眼的组合物 |
KR101892865B1 (ko) * | 2017-08-16 | 2018-08-28 | 계명대학교 산학협력단 | 마퀴베리를 유효성분으로 함유하는 아토피성 피부염 예방 또는 치료용 조성물 |
JP7311160B2 (ja) | 2017-08-18 | 2023-07-19 | アクリビスタ エルエルシー | ドライアイ症候群を診断及び処置する方法及びヒトの眼を処置するための組成物 |
EA202091446A1 (ru) | 2018-01-12 | 2021-01-29 | Метимеди Фармасьютикалз Ко., Лтд. | Способы лечения хронических воспалительных заболеваний |
KR102556874B1 (ko) * | 2018-02-14 | 2023-07-18 | 동국제약 주식회사 | 비스포스포네이트 및 콜레칼시페롤을 함유하는 경구용 에멀젼 조성물 및 그 제조방법 |
KR20220163519A (ko) * | 2018-02-28 | 2022-12-09 | 산텐 세이야꾸 가부시키가이샤 | 디쿠아포솔 및 양이온성 폴리머를 함유하는 안과용 조성물 |
US20220023209A1 (en) * | 2018-12-06 | 2022-01-27 | Lipicare Life Sciences Ltd. | Vitamin d micro-emulsioins and uses thereof |
US11278493B2 (en) * | 2018-12-10 | 2022-03-22 | EternaTear, Inc. | Ophthalmic formulations providing durable ocular lubrication |
EP3919052A4 (en) * | 2019-01-09 | 2022-10-05 | Fuso Pharmaceutical Industries, Ltd. | PHARMACEUTICAL COMPOSITION FOR INTRAOCULAR OR ORAL ADMINISTRATION FOR THE TREATMENT OF RETINAR DISEASES |
US20200345805A1 (en) * | 2019-04-22 | 2020-11-05 | Allegro Ophthalmics, Llc | Compositions and methods useable for treatment of dry eye |
IT201900007202A1 (it) * | 2019-05-24 | 2020-11-24 | Pavia Farm S R L | Composizione a base di vitamine liposolubili ad elevato assorbimento enterico |
RU2706703C1 (ru) * | 2019-08-19 | 2019-11-20 | Общество с ограниченной ответственностью "ПРОФИТ ФАРМ" | Раствор увлажняющий офтальмологический |
GB202010829D0 (en) * | 2020-07-14 | 2020-08-26 | Exonate Ltd | Compounds for treatment of neovascular diseases |
CN111973554A (zh) * | 2020-09-03 | 2020-11-24 | 浙江目中明生物科技有限公司 | 一种护眼水 |
US11951123B2 (en) | 2022-01-12 | 2024-04-09 | Platform Ophthalmic Innovations, LLC | Fortified nutritional lubricating drops for dry eye disease |
US11679078B1 (en) | 2022-03-08 | 2023-06-20 | EternaTear, Inc. | Ophthalmic formulations and related methods |
US11471475B1 (en) | 2022-03-08 | 2022-10-18 | Ralph P. Stone | Ophthalmic suspension vehicles and related methods for pharmaceutical ingredient delivery |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3102593A1 (de) * | 1981-01-27 | 1982-09-02 | Dr. Thilo & Co GmbH, 8021 Sauerlach | Arzneimittelzubereitung zur anwendung am auge |
JP3410364B2 (ja) * | 1997-05-14 | 2003-05-26 | 千寿製薬株式会社 | ジフルプレドナート含有組成物 |
AU2792997A (en) * | 1997-05-26 | 1998-12-30 | New Vision Co., Ltd. | Medicinal compositions for topical administration containing vitamin d and vitamin k |
US5981607A (en) | 1998-01-20 | 1999-11-09 | Allergan | Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers |
FR2823441B1 (fr) * | 2001-04-12 | 2004-09-10 | Thea Lab | Composition pharmaceutique a base de macrolides pour application locale en ophtalmologie et son procede de preparation |
WO2004098592A1 (ja) * | 2003-05-06 | 2004-11-18 | Senju Pharmaceutical Co. Ltd. | オキサゾリジノン誘導体含有組成物 |
EP1655021B1 (en) | 2004-11-09 | 2008-10-29 | Novagali Pharma SA | Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential |
CN100478025C (zh) * | 2005-03-25 | 2009-04-15 | 中国科学院上海药物研究所 | 一种环孢菌素a眼用微乳制剂及其制备方法 |
WO2008035246A2 (en) * | 2006-07-28 | 2008-03-27 | Novagali Pharma Sa | Compositions containing quaternary ammonium compounds |
CN101028240B (zh) | 2007-03-29 | 2010-06-09 | 中国科学院上海药物研究所 | 眼用微乳/亚微乳原位凝胶制剂及其制备方法 |
US8512687B2 (en) * | 2007-07-09 | 2013-08-20 | Novagali Pharma Sa | Oil in water emulsion comprising NSAIDs and quaternary ammonium halides |
JP2011502990A (ja) * | 2007-11-05 | 2011-01-27 | ボーシュ アンド ローム インコーポレイティド | 薬物送達用ビヒクルとしての水非混和性物質 |
CN101385697B (zh) * | 2008-10-30 | 2012-10-03 | 中国科学院上海药物研究所 | 氟比洛芬酯眼用纳米乳-原位凝胶制剂及其制备方法 |
AU2010256652B2 (en) * | 2009-06-05 | 2015-11-26 | Allergan, Inc. | Artificial tears and therapeutic uses |
IT1404931B1 (it) * | 2010-06-11 | 2013-12-09 | Medivis S R L | Composizioni oftalmiche per la somministrazione di principi attivi liposolubili . |
CN102370617B (zh) * | 2010-08-13 | 2013-09-11 | 中国科学院上海药物研究所 | 石杉碱甲眼用微乳制剂及其制备方法 |
CN103282044B (zh) * | 2010-12-28 | 2016-07-06 | 韩林制药株式会社 | 纳米乳剂形态的眼科用组合物 |
ES2736256T3 (es) * | 2011-03-14 | 2019-12-27 | Drug Delivery Solutions Ltd | Composición oftálmica |
JP2013018764A (ja) | 2011-07-14 | 2013-01-31 | Kao Corp | 上皮型ナトリウムチャネル活性化剤 |
ES2751248T3 (es) * | 2011-11-24 | 2020-03-30 | Toyo Sugar Refining Co Ltd | Agente protector queratoconjuntival o agente inhibidor de trastornos queratoconjuntivales |
HUE049489T2 (hu) | 2011-12-07 | 2020-09-28 | Allergan Inc | Hatékony lipidbevitel emberi könnyfilmbe sóérzékeny emulziós rendszer alkalmazásával |
US20150133472A1 (en) * | 2012-05-11 | 2015-05-14 | Cipla Limited | Pharmaceutical composition |
JP5084967B1 (ja) * | 2012-06-08 | 2012-11-28 | ライオン株式会社 | 高吸着性ビタミンa含有ナノエマルション粒子を含む眼科用組成物及びその製造方法 |
WO2014098092A1 (ja) | 2012-12-18 | 2014-06-26 | オリザ油化株式会社 | ドライアイ予防・治療剤 |
ES2673009T3 (es) | 2013-03-14 | 2018-06-19 | EyeCRO, LLC | Plataforma de suministro tópico de microemulsiones |
WO2014153733A1 (en) | 2013-03-27 | 2014-10-02 | Comprehensive Drug Enterprises, Ltd. | Ophthalmic composition, method for preparing the same, and use of the same |
KR101492447B1 (ko) * | 2013-05-20 | 2015-02-23 | 주식회사태준제약 | 사이클로스포린을 함유하는 나노에멀젼 점안 조성물 및 그의 제조 방법 |
KR101890503B1 (ko) | 2014-05-01 | 2018-08-21 | 인티그럴 바이오시스템스 엘엘씨 | 안구 장애의 치료를 위한 막-부착성 자가-조립된 시스템 |
CN105496955A (zh) * | 2015-12-11 | 2016-04-20 | 北京蓝丹医药科技有限公司 | 一种二氟泼尼酯眼用乳剂及其制备方法 |
CN105726479B (zh) * | 2016-03-24 | 2018-06-22 | 北京茗泽中和药物研究有限公司 | 环孢素眼用乳剂 |
CN105663141B (zh) | 2016-03-24 | 2018-06-15 | 北京茗泽中和药物研究有限公司 | 二氟泼尼酯眼用乳剂 |
-
2016
- 2016-07-07 EP EP16382321.4A patent/EP3266446B1/en active Active
- 2016-07-07 ES ES16382321T patent/ES2706535T3/es active Active
- 2016-07-07 LT LTEP16382321.4T patent/LT3266446T/lt unknown
- 2016-07-07 PT PT16382321T patent/PT3266446T/pt unknown
- 2016-07-07 PL PL16382321T patent/PL3266446T3/pl unknown
- 2016-07-07 DK DK16382321.4T patent/DK3266446T3/da active
- 2016-07-07 JO JOP/2017/0147A patent/JOP20170147B1/ar active
- 2016-07-07 RS RS20190077A patent/RS58292B1/sr unknown
- 2016-07-07 SI SI201630160T patent/SI3266446T1/sl unknown
-
2017
- 2017-07-06 RU RU2017123797A patent/RU2756758C2/ru active
- 2017-07-06 JP JP2017132403A patent/JP7224095B2/ja active Active
- 2017-07-07 CN CN201710551883.9A patent/CN107582605A/zh active Pending
- 2017-07-07 US US15/644,286 patent/US10660848B2/en active Active
-
2019
- 2019-01-04 HR HRP20190036TT patent/HRP20190036T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
CN107582605A (zh) | 2018-01-16 |
LT3266446T (lt) | 2019-01-25 |
ES2706535T3 (es) | 2019-03-29 |
JP2018039781A (ja) | 2018-03-15 |
US10660848B2 (en) | 2020-05-26 |
RU2017123797A3 (da) | 2020-09-18 |
PL3266446T3 (pl) | 2019-05-31 |
JP7224095B2 (ja) | 2023-02-17 |
PT3266446T (pt) | 2019-01-30 |
JOP20170147B1 (ar) | 2021-08-17 |
EP3266446B1 (en) | 2018-11-21 |
RU2756758C2 (ru) | 2021-10-05 |
HRP20190036T1 (hr) | 2019-02-22 |
RU2017123797A (ru) | 2019-01-09 |
JOP20170147A1 (ar) | 2019-01-30 |
RS58292B1 (sr) | 2019-03-29 |
SI3266446T1 (sl) | 2019-02-28 |
EP3266446A1 (en) | 2018-01-10 |
US20180008538A1 (en) | 2018-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3266446T3 (da) | Øjenpræparat omfattende ricinusolie og triglycerid med mediumkæde | |
CN108273065B (zh) | 一种眼用组合物 | |
Ahmed et al. | Ocular drug delivery: a comprehensive review | |
US11583549B2 (en) | High elasticity hyaluronan compositions and methods of use thereof | |
KR101786760B1 (ko) | 프로스타글란딘을 함유하는 음이온성 수중유형 에멀젼 및 그의 용도 | |
JP6824270B2 (ja) | 生物活性親油性化合物を有するpeg化脂質ナノ粒子 | |
EP3145511B1 (de) | Zusammensetzung zur behandlung des auges | |
KR101813211B1 (ko) | 프로스타글란딘을 함유하는 양이온성 수중유형 에멀젼 및 그의 용도 | |
CN110090294A (zh) | 具有改善的干燥保护和保留的眼用组合物 | |
EP3412276A2 (de) | Zusammensetzung zur behandlung des trockenen auges | |
US20180221407A1 (en) | Ophthalmic compositions for therapeutic and prophylactic uses | |
WO2013046059A2 (en) | Methods and compositions for tamarind-based ocular disease treatment in combination with trehalose | |
EP3638219B1 (en) | Composition comprising terpinene-4-ol for the treatment of demodicosis | |
US20210386679A1 (en) | Artificial tears | |
JP7065895B2 (ja) | クロベタゾールの水中油型ナノエマルジョン組成物 | |
WO2010031096A1 (de) | Antimikrobiell und antiviral wirkende zusammensetzunq | |
EP4302767A1 (en) | Ophthalmic composition comprising eriocitrin | |
WO2024110503A1 (en) | Methods for treating eyetear film deficiency | |
EP3761986A1 (en) | Methods of use and pharmaceutical compositions of a selective syk inhibitor | |
CA3173219A1 (en) | Ophthalmic formulation and its use | |
CN112294761A (zh) | 一种难溶性药物的眼用胶束制剂 | |
DE202014011522U1 (de) | Zusammensetzung zur Behandlung des Auges |